Harbour BioMed has entered into an agreement with ImmunoChina Pharmaceuticals Co. to develop fully human monoclonal antibody fragments for use in Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy. Under the agreement, ImmunoChina receives rights to use the fully human antibody fragments discovered by Harbour BioMed through its H2L2 transgenic mouse platform for the development of CAR-T based therapeutic solutions. Harbour will receive an upfront payment and milestones as well as royalties based on net sales. Specific financial details were not disclosed.